Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT.

Bone marrow transplantation·2023

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Scientific reports·2023

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Bone marrow transplantation·2020

Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.

Bone marrow transplantation·2019

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Leukemia·2019

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Annals of hematology·2017

BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection.

British journal of haematology·2026

Development and validation of a machine learning model based on routine laboratory tests for predicting FLT3-ITD mutations in acute myeloid leukaemia.

British journal of haematology·2026

Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial.

British journal of haematology·2026

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.

British journal of haematology·2026

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.

British journal of haematology·2026

Correction: Induced pluripotent stem cells as natural biofactories for exosomes carrying miR-199b-5p in the treatment of spinal cord injury.

Frontiers in pharmacology·2026

Repetitive transcranial magnetic stimulation: advances for psychiatric disorders.

Frontiers in psychiatry·2026

Advances in the clinical application of stellate ganglion block for non-pain indications.

Frontiers in medicine·2026

Correction: In-network multidisciplinary digital care improves outcomes in medicare advantage members with musculoskeletal diagnoses.

Frontiers in digital health·2026

Adaptation of the Yield-Scaling Factor to Reduce Target Yield Deviation and Donation Time in Pathogen-Reduced Apheresis Platelet Collections Using the Sysmex XN1000 Blood Bank Mode.

Annals of laboratory medicine·2026

The Trodden and Untrodden Path: Mentorship, Innovation, and Leadership in Dermatology.

Dermatologic clinics·2026

Related Experiment Videos

Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)

Related Concept Videos

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT.

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection.

Development and validation of a machine learning model based on routine laboratory tests for predicting FLT3-ITD mutations in acute myeloid leukaemia.

Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial.

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.

Correction: Induced pluripotent stem cells as natural biofactories for exosomes carrying miR-199b-5p in the treatment of spinal cord injury.

Repetitive transcranial magnetic stimulation: advances for psychiatric disorders.

Advances in the clinical application of stellate ganglion block for non-pain indications.

Correction: In-network multidisciplinary digital care improves outcomes in medicare advantage members with musculoskeletal diagnoses.

Adaptation of the Yield-Scaling Factor to Reduce Target Yield Deviation and Donation Time in Pathogen-Reduced Apheresis Platelet Collections Using the Sysmex XN1000 Blood Bank Mode.

The Trodden and Untrodden Path: Mentorship, Innovation, and Leadership in Dermatology.

Related Experiment Videos

Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)

Related Concept Videos

Related Articles